Skip to main content
SpringerLink
Log in

Bortezomib beim Myelom: Seltener ist besser

  • Literatur kompakt_Leukämien und Lymphome
  • Published:
Im Focus Onkologie Aims and scope

Welches ist das optimale Dosisregime für Bortezomib in Kombination mit Melphalan und Prednison (VMP)? Die Antwort auf diese Frage liefern die Ergebnisse einer retrospektiven Analyse von drei Phase-III-Studien.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Mateos MV et al. Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. Haematologica. 2014;99(6):1114-22.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Judith Neumaier

Authors
  1. Judith Neumaier
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Neumaier, J. Bortezomib beim Myelom: Seltener ist besser. Im Focus Onkologie 17, 22 (2014). https://doi.org/10.1007/s15015-014-1483-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-014-1483-5

Search

Navigation